Design with confidence supported by empirical site-specific evidence
Literature, vendor data, and modelling can indicate that a treatment pathway is plausible, but they rarely define how it will respond to site-specific variability, extended operation, upset conditions, or scale transition. These uncertainties affect technology selection, process configuration, reagent demand, residuals generation, equipment sizing, permitting evidence, and the reliability of the capital basis.
Bench and pilot-scale testing generate empirical evidence under controlled, representative conditions. Testing can evaluate performance across expected operating ranges, expose sensitivities and failure modes, and determine whether assumed process behavior remains credible as conditions change. The resulting evidence supports treatment decisions based on observed site response rather than idealized or vendor-reported performance. Common challenges we help project development teams resolve include:
- Treatment or process concepts rely on assumed performance without testing under representative conditions.
- Laboratory data are insufficient to understand variability, failure modes, or operating limits.
- Scale-up risks are not clearly characterized before capital or permitting decisions are made.
- Regulatory reviewers seek empirical evidence where modelling or literature alone is insufficient.
- Test results are generated without clear linkage to decision thresholds or next-step criteria.
- Early testing assumptions are treated as definitive despite limited duration or scope.
English